Beacon Biosignals announced a strategic collaboration with Skye Bioscience to enhance its upcoming CBEYOND Phase 2 clinical trial of Nimacimab. This partnership will incorporate sleep quality and sleep apnea endpoints via the Beacon Platform and the FDA 510(k)-cleared Dreem 3S EEG device to better understand the comprehensive impact of Nimacimab on patients with obesity. “We are thrilled to collaborate with Skye Bioscience to bring our expertise in sleep monitoring and analysis to this important clinical trial,” said Jacob Donoghue, MD, PhD, CEO of Beacon Biosignals. “Our FDA-cleared Dreem 3S EEG headband and AI-powered analytics platform will enable the collection of clinically-validated sleep assessments from patients in their own homes. This will provide valuable insights into how Nimacimab may improve sleep quality and reduce sleep apnea, conditions often comorbid with obesity and cardiometabolic disease.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKYE:
- Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
- B. Riley reiterates Buy on Altimmune, Arrowhead after danuglipron given nod
- Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th
- Skye Bioscience to host KOL event on CB1 Inhibition
- Skye Bioscience establishes metabolic clinical, scientific advisory board
Questions or Comments about the article? Write to editor@tipranks.com